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Abstract 
ClpB is a molecular chaperone that is essential for infectivity and pathogen survival in a 
host. It belongs to the AAA+ protein family, which cooperates with the DnaK chaperone system 
to reactivate aggregated proteins. In this study, we purified and then studied the biochemical 
properties of the apicoplast targeted ClpB isoform from the malaria parasite Plasmodium 
falciparum: PfClpB1. Plasmodium falciparum is the parasite responsible for the most severe 
form of malaria. In contrast to the parasitophorous vacuole targeted PfClpB2 from Plasmodium 
falciparum which contains all characteristic AAA+ sequence motifs, PfClpB1 also includes a 52-
residue long non-conserved insert in the middle domain. The ATPase activity study shows that 
PfClpB1 hydrolyzes ATP in presence of Poly-lysine and α-casein. Similar to most AAA+ 
ATPases, addition of ATP induces hexamer formation in PfClpB1. Lastly, PfClpB1 reactivates 
aggregated firefly luciferase. However, PfClpB1 is unable to efficiently reactivated luciferase in 
the presence of the E. coli DnaK chaperone system or human Hsp70 and Hsp40 (Hdj1). This can 
be explained by the extra middle domain sequence of PfClpB1. Our data may suggest that 
PfClpB1 activity is essential for Plasmodium falciparum survival by preserving the activity of 
apicoplast proteins. 
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Chapter 1 - Introduction 
1.1 Malaria 
The history of malaria predates humanity. This conclusion can be inferred from the 
discovery of mosquitos in Baltic amber stones dating from 40 to 60 million years. Malaria comes 
from the Italian word “malaria” which means bad air.  The etymology of the word is related to 
the fact that the ancient Romans though the disease was caused by the foul air coming from the 
swamps [1]. Reference to the ravage caused by malaria has been recorded through history [2]. 
During World War II and the Vietnam War most casualties in the US army was mainly caused 
by malaria rather than bullets. 
According to the Centers for Disease Control and Prevention (CDC) [3], malaria is 
caused by the genus Plasmodium which spends parts of its life cycle between two hosts: humans 
and mosquitos. Plasmodium falciparum is responsible for most deaths in Africa. Plasmodium 
vivax is more geographically widespread and the symptoms are less severe. Plasmodium 
malariae persists in the human blood for a long period, possibly a decade [4]. From the genus of 
plasmodium, Plasmodium falciparum is the most virulent [5]. Malaria is an endemic disease in 
Asia, Africa, India, South and Latin America (Figure 1.1 ). People in non-endemic area often get 
the disease during travel. 
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Figure 1.1 Malaria endemic countries 
The map represents the spread of malaria infection in the world. The more predominant endemic 
areas are Africa, South America, Asia and India. 
(http://www.nature.com/nature/journal/v484/n7395_supp/interactive/malaria.html) 
1.1.1 Malaria disease 
The most vulnerable groups to malaria are children under 5 year's old, pregnant women, 
and people living with HIV [6]. According to the World Health Organization in 2008 [7], 89 % 
of the deaths are from Africa, 5% from Southeast Asia, 6% from Eastern Mediterranean. The 
main symptoms are: fever, sweating, headache, convulsion, chills, and muscle pain. 
Complication can arise such as hemolytic anemia: destruction of blood cells, liver and kidney 
failure. Sometimes rupture of the spleen can occur. 
For thousands of years, malaria has been treated with herbal remedies. Quinine was the 
first effective treatment, which was quickly replaced by chloroquinine which has fewer side 
effects [8]. Today, the choice of medication depends on where you live, because of the 
development of antimalarial drug resistance in Plasmodium [9]. Novel approaches need to be 
developed to fight the disease, since antimalarial drug resistance is becoming a serious issue. The 
genome of P. falciparum clone 3D7 was the first to be sequenced and annotated in 2002. The 
nuclear genome is A+T rich, with an overall composition of 81% of A+T [10]. The components 
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of some anabolic pathways for the synthesis of lipid and iron sulfur complexes seem to be 
localized to the apicoplast [11, 12]. The function of apicoplast will be discussed later. 
1.1.2 Life cycle of Plasmodium falciparum 
The complexity of the Plasmodium life cycle resides in the fact that it requires two hosts: 
female mosquito and human host (Figure 1.2 ). During the liver stages, anopheles has a blood 
meal and injects sporozoites into the human bloodstream until they reach the liver cell. In the 
infected liver cells, sporozoites mature and develop into schizonts, which will burst out of the 
cells as merozoites. At the next stage: the human blood stages, the released merozoites infect 
red blood cells. In this stage, we have two scenarios at play. After infection of red blood cells, 
the mature merozoites can divide and infect some new red blood cells or they can differentiate 
into gametocytes. The anophele will ingest the gametocytes during the mosquito stages. Female 
and male gametocytes will then form an oocyst, which will mature to release new sporozoites 
that will infect the liver and the plasmodium life cycle will repeat indefinitely. The human blood 
stage is responsible for malaria. The internment and synchronous lysis of the red blood cells is 
responsible for the fever during malaria [13]. In addition, Plasmodium falciparum is a deadly 
disease because of its capability to cause severe anemia. Infected red bloods undergo 
morphological changes and can block blood flow to vital organs such as the brain: leading to 
cerebral malaria [86]. 
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Figure 1.2 Life cycle of Plasmodium falciparum 
The life cycle is divided into 3 stages: Mosquito stages, human liver stages, and human blood 
stages. Plasmodium falciparum requires human and mosquisto host to complete its full life-
cycle. (1): Human host infection, (2): Invasion liver cells, (4): Rupture of infected liver cells, (5): 
Infection of red blood cells, (6): Division and multiplication, (7): Sexual forms cycles, (8): 
Transfer gametocytes into mosquito, (11): Formation oocyst, (12): release of sporozoites. 
(http://www.dpd.cdc.gov/dpdx/HTML/malaria.htm) 
 
1.2 Caseinolytic peptidase B (ClpB) 
Caseinolytic peptitase B (ClpB) is heat shock protein that is involved in the 
disaggregation of mis-folded protein in several organisms [14, 15, 16]. ClpB is an ATP 
dependent molecular chaperone that belongs to the AAA+ superfamily of ATPase [17]. It is 
found in eukaryotic and prokaryotic cells and cooperates with the KJE chaperone system (DnaK, 
DnaJ, and GrpE) to disaggregate and refold proteins [18]. Many ATPases such as ClpA, ClpX, 
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ClpE, ClpP and ClpL form a complex with a peptidase unit, but ClpB does not associate with a 
peptidase unit and does not participate in protein degradation [19]. 
1.2.1 AAA+ superfamily protein ATPase 
The hallmark of the AAA+  family of protein (ATPases Associated with diverse cellular 
Activities) is a 200-250 amino-acid ATP binding domain that contains different conserved 
motifs: Walker A, Walker B, N-linker, the second region of homology, the pore region, Sensor 1 
and 2 [20]. AAA+ protein are involved in different cellular processes which range from protein 
disaggregation, degradation, DNA replication and thermo-tolerance. AAA+ proteins function as 
oligomers, but the extent of the mechanism of nucleotide binding and hydrolysis are still ill 
defined. It is usually assumed that Walker A and B are involved in ATP binding and hydrolysis 
[21].  AAA+ domain consists of an N-terminal nucleotide-binding subdomain and a smaller C-
terminal helical subdomain. The αβα fold with five parallel β sheets characterizes the N-terminal 
subdomain. The α-helix of the C-terminal subdomain is one of main features of AAA + proteins 
that differentiate it from other nucleotide-binding proteins [22]. All AAA+ proteins are classified 
depending of the number of conserved AAA+ domains (nucleotide binding domains). A Class I 
has two AAA+ domains, when a class II has one AAA+ domain (Figure 1.3) [23]. 
 
N-terminal AAA+ domain Middle-domain AAA+ domain 
Class I: ClpB 
N-Terminal AAA+ domain 
Class II: ClpX 
Figure 1.3 The domain structures of the Clp ATPases 
 
1.2.2 Structure and function of ClpB domains 
ClpB is a molecular chaperone with multiple domains. Like other AAA-type ATPases, 
ClpB contains two nucleotide binding domains (NBDs), including a Walker A and B consensus 
sequences, an arginine finger motif, the pore loop and the sensor 1 and 2 [24]. To achieve full 
disaggregation of stress-damaged protein, ClpB cooperates with the KJE chaperone system 
(DnaK, DnaJ, GrpE). Walker A and B coordinate ATP bonding and hydrolysis. The arginine 
finger is necessary for nucleotide hydrolysis and oligomerization. Sensor 1 and 2 also assist with 
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nucleotide binding and hydrolysis. Finally, the pore loop is required for substrate binding, 
translocation and disaggregation activity [25].  The Middle-domain is speculated to facilitate 
protein disaggregation [26, 27]. Despite major advance in our understanding of the middle-
domain, some of its functions still remain elusive 
Protein aggregates binds to the ClpB hexamers in the presence of ATP. Before 
translocation is initiated, the KJE (DnaK, DnaJ and GrpE) system must interact with the Middle 
domain of ClpB to commit to the interaction between the pore loop of NBD1 and aggregates 
[28]. Then ATP hydrolysis is followed by translocation of the aggregates through the central 
channel of ClpB. The mechanism was discovered by constructing a ClpB mutant: BAP that 
could bind to ClpP [29]. If aggregates are hard to unfold, ClpB hexamers will try a different 
position to pull the aggregates through the central channel. 
The N-terminal domain of ClpB is more mobile that the rest of the protein (Figure 1.5 ). 
The N-terminal is required for protein disaggregation of some substrates in vitro and in vivo [30, 
31]. Furthermore mutation or deletion of the N-terminal domain blocked activation of ATPase of 
ClpB by α-casein [32, 33]. It has been speculated that the mobility of ClpB allows it to interact 
efficiently with the substrate and Dnak. The N-terminal domain of ClpB may play a role in 
substrate specificity. The increase mobility of the N-terminal domain can result in increased 
chaperone activity. In short, the N-terminal domain is required for aggregate binding and is also 
important for protein disaggregation. 
The middle domain is less mobile than the N-terminal domain. It is located between two 
nucleotide binding domains (Figure 1.4 ). The presence of the middle domains helps to stabilize 
the oligomers [34]. The function of the middle domain is still unknown. One model proposes that 
the middle domain facilitates the interaction between KJE and ClpB [35, 36]. It was observed 
that lack of cooperation between the Middle domain and the KJE system stop the reactivation of 
aggregates [37].  The most recent studies confirm that the middle domain is responsible for the 
species specific cooperation with the Hsp 70 system [38, 39]. 
The C-terminal domain of ClpB is made principally of α-helices and linked to the second 
nucleotide binding domain. The C-terminal is also required for oligomerization [40, 41, and 42]. 
It is being proposed that the C-terminal domain binds to some substrates and it is therefore called 
the sensor domains [43]. 
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The two nucleotide binding domains NBD1 & NBD2 are the essential part of the ClpB 
machine. NBD1 and NBD2 undergo conformational change during translocation to allow the 
passage of unfolded polypeptides through the central channel [44].  In a recent study, wild type 
ClpB was mixed with an inactive mutant, ClpB chaperone activity was blocked in the presence 
of co-chaperone with some substrates, indicating the requirement of cooperation between 
subunits of ClpB hexamer [45]. 
                                                  
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
 
Figure 1.4 ClpB domains 
The figure shows the main domain of ClpB. The N-terminus, the Middle domain and the two 
AAA+ domains.  
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Figure 1.5 The structure and mobility of Thermus thermopholis ClpB domains 
The N-terminal domain is shown in yellow color. The Middle domain is in purple color. The 
blue and green color represents the nucleotide binding domains. (A) The different conformation 
of TClpB. (B) Degree of mobility of each domain with TClpB molecule 1, 2, 3 superimposed 
through the atoms of NBD2. The higher mobility of the N-terminal domain allows it to react 
with substrate in different conformation during binding. (Cell, Vol. 115, 229–240, October 17, 
2003, Copyright 2003 by Cell Press The Structure of ClpB: A Molecular Chaperone that Rescues 
Proteins from an Aggregated State) 
1.2.3 Cell stress and protein aggregation 
Classical “molecular chaperones” such as Hsp40, Hsp60, Hsp70, Hsp90 and Hsp100 
assist in promoting protein degradation after stress or injury and facilitate protein folding (Table 
1.1), but they cannot mediate protein disaggregation. Heat-shock response can be caused by 
circumstances as diverse as viral and bacterial infection or exposure to transition heavy metals 
and oxidants [46]. The transcription of heat-shock genes is regulated by an array of stress 
conditions. First of all, there are environmental stresses such as toxic chemical, drugs, heat 
shock. Next, there are cell growth and cycle, differentiation and activation of cells by some 
oncogenes. Finally, there are pathophysiological stresses such as fever, inflammation and 
infection [46]. However, ClpB “has the remarkable capacity to rescue proteins from aggregated 
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state by mediating disaggregation of stress-damaged proteins” [47].  The DnaK/Hsp 70 
chaperone system is required for full recovery of active protein [48] ClpB uses ATP-driven 
conformational change to mediate the disaggregation of protein (Figure 1.6 ). Stress-damaged 
proteins arising from partially folded intermediates are inclusion bodies, thermal aggregates and 
refolding aggregates. In vitro, protein aggregation is responsible for protein instability, in vivo 
protein aggregation promote formation of disordered aggregates [49]. 
 
Table 1.1 Heat shock proteins in eukaryotes. 
(Whitley, D., Goldberg, S., and Jordan, N. (1998). “Heat shock proteins: A review of 
the molecular chaperone.” J. Vasc Surg. 29:748-751) 
 Molecular size 
(kDa) 
Location Major functions 
Hsp40 40 Cytosol/nucleus/ 
Mitochondria 
Stabilization of mis-folded 
proteins, co-chaperone for Hsp70 
Hsp60 60 Cytosol/nucleus Protein folding (limited substrates 
in eukaryotic cytoplasm) 
Hsp70 70 Cytosol/nucleus Protein folding, membrane 
transport of proteins. 
Hsp90 90 Cytosol/nucleus Regulatory interaction with 
signaling proteins, stabilization of 
misfolded proteins 
Hsp100 100 Cytosol/nucleus Protein disaggregation, 
thermotolerance 
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Figure 1.6 Mechanism of protein disaggregation mediated by ClpB 
The Cylinders with a central channel represent the ClpB hexamer. ATP hydrolysis is required to 
pull the aggregates through the channel. The ClpB hexamer and the KJE chaperone system 
facilitate the insertion of aggregates into the central channel. 
1.2.4 Biochemical properties of ClpB 
The crystal structure of Thermus thermophilus ClpB has been solved and provides 
valuable tools to link structure to function (Figure 1.5 ) [50]. The ClpB monomer is about 95 
KDa with multiple domains. ClpB forms hexamers that are stabilized by ATP binding and 
hydrolysis [51]. Full reactivation of insoluble aggregated proteins by ClpB requires the 
assistance of the chaperone helpers: DnaK, DnaJ and GrpE [85]. Substantial evidence of ClpB 
involvement in pathogenic microorganism virulence has been reported.  
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1.3 ClpB protein needed for infectivity 
Like many other pathogenic organisms, the malaria parasite Plasmodium falciparum is 
subjected to hostile environment during infection in the human host. The environmental stressors 
are temperature, pH, reactive nitrogen, oxidative stress, salt concentration. Stressful condition 
acts as a stimulus to induce change in gene expression and transcription. Although the molecular 
mechanism for survival in the host cell is not clearly understood, some of the genes that are 
necessary for multiplication and expansion of the disease are well known. During infection, most 
bacteria up-regulate the expression of heat shock protein to cope with challenging cellular stress 
in their host [52]. One of those proteins is ClpB which helps to disaggregate mis-folded 
intracellular proteins because of stressful condition. ClpB chaperone is highly conserved across 
prokaryotes and eukaryotes. ClpB is involved in stress response in various bacteria. For instance 
in E. coli, ClpB is required for thermo-tolerance with the assistance of DnaK, DnaJ and GrpE. 
The heat shock protein or Hsp can vary from organism to organism. In Drosophila melanogaster, 
Hsp70 provides stress protection. Previous studies show that classical heat shock proteins are 
necessary for the pathogenicity of mycobaxterium tuberculosis [53, 54, 55].  Heat shock is 
known to confer thermo-tolerance to bacteria. Hsp 100 (ClpB) in Leishmania donovani is 
responsible for the differentiation from promastigotes (insect stages) to amastigotes (mammalian 
stages). Its absence shifts the balance toward promastigotes. So, The ClpB gene is required for 
full amastigote development and during first stages of a mammalian infection [56]. Loss of 
Hsp100 in leishmania major retards lesion development in infected mice, because Hsp 100 is 
important for thermotolerance during the mammalian stage, when cellular stress is intense. 
Absence of Hsp100 affects infectivity and impaired asmatigote development [57].  In 
Staphylococcus aureus and P.gingivalis, ClpB is associated with intracellular survival and 
multiplication [58, 59].  The lack of ClpB in L. monocytogenes and P. gingivalis attenuated 
virulence in murine model of infection [60, 61]. Finally, Inactivation of ClpB in Leptospira 
interrogans is involved in general stress response and directly or indirectly reduces virulence 
[62]. Thus, the data clearly demonstrate that ClpB is required for the infectivity and virulence of 
the disease in different organisms. Since ClpB does not exist in humans, it might be a good target 
for the development of therapeutic drug. For instance, the development of antibodies specific for 
Flavobacterium psychrophilum ClpB may be useful for protective immunity from bacterial 
disease in coldwater [63]. 
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1.4 Apicoplast organelle 
1.4.1 Origin and function of the apicoplast 
In 1975, Araaxie Kilejian found the first evidences that ultimately confirm the existence 
of a plastid in Plasmodium. Under the microscope, she saw an extra-chromosomal DNA 
molecule in Plasmodium [64]. The apicoplast is derived from two serial endosymbiotic events 
(Figure 1.7 ).  The primary endosymbiotic event occurred between a nucleated biciliate 
phagotroph and a photosynthetic cyanobacterium bounded by two membranes. This process gave 
rise to several organisms: red algae, green algae and land plants.  The second endosymbiosis 
involved the engulfment and retention of a red alga by a second phagotroph giving rise to P. 
falciparum [65, 66]. The process of a phagotrophic host cell engulfing, retaining and ultimately 
enslaving another cell is called endosymbiont. Thus, apicoplast is an endosymbiont: an organism 
living in another living organism (Plasmodium falciparum).  The function of the apicoplast was 
discovered by identifying genes necessary for fatty acid biosynthesis [67]. Soon after, it was also 
discover that apicoplast has a pathway to synthesize isopentenyl diphosphate, a precursor of 
isoprenoids [68]. Finally, the iron sulphur complexes were discovered through data mining [69]. 
Consequently, the apicoplast supplies carbon, energy and reducing power in a similar way to 
algal plastid. An understanding of the machinery involved in translocating proteins across the 
four membranes surrounding the apicoplast is coming to light. 
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Figure 1.7 The concept of endosymbiosis 
The chromalveolate hypothesis can explain some endosymbiotic events in dinoflagellates. 
(Chan, C. X. & Bhattacharya, D. (2010) The Origin of Plastids. Nature Education 3(9):84) 
1.4.2 Apicoplast targeting sequence 
 Bipartite apicoplast-targeting leaders start with a signal peptide [70]. Transit peptides are 
adjacent to the signal peptides and exhibit a surplus of basic over acidic residues, and they tend 
to be enriched for Asparagines and/or Lysines (Figure 1.8 ). Apicoplast proteins use the co-
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translational translocation pathway. They are imported into the ER, and their import is directed 
by an N-terminal signal sequence or an internal signal sequence.  The transit peptide domain of 
luminal proteins is bound at the ER by a receptor protein that directs these proteins into vesicles. 
These vesicles are directly exported to the apicoplast where they fuse with its outer membrane. 
The specific mechanisms that direct the distribution of the proteins to the organelle are still 
unknown. The apicoplast targeting signal is cleaved during transport to the apicoplast. 
 
SP TP Mature Protein 
Figure 1.8 Schematic representation of a typical apicoplast-targeted protein 
The mature protein remains after cleavage of the signal and transit peptide. 
SP: signal peptide, TP: transit peptide. 
1.4.3 Apicoplast needed for infectivity 
The P. falciparum apicoplast is required for survival of the parasite in both its 
erythrocytic [71] and liver stages [72, 73]. The apicoplast is a non-photosynthetic organelle that 
is involved in several biochemical pathways, such as biosynthesis of fatty acids, iron-sulfur 
cluster and isoprenoids [74]. Two different lines of evidence demonstrated that apicoplasts is 
required for parasite survival. First, any chemical affecting apicoplast metabolisms resulted in 
the death of parasite. Second, the inability to replicate the apicoplast also resulted in death. 
Surprisingly, the parasite is able to survive with a damaged apicoplast, but only die in the next 
generation. This is called “delayed death”.  One probable hypothesis is that apicoplast secretes a 
molecule that is needed for the infection. Plant scientists are trying to develop non-toxic 
herbicides that may act upon the apicoplast, by using tools such as bioinformatics and 
experimental approaches. Because apicoplasts share similitude with chloroplasts and 
prokaryotes, they strike as an attractive target for known antibiotics. The non-mammalian 
characteristics of the apicoplast make it a perfect target for anti-malarial drugs [75]. 
1.5 Plasmodium Falciparum ClpB homologue (PfClpB1) 
1.5.1 Up regulation of PfClpB1 during malaria 
The ClpB protein plays an important role in the cell homeostasis. During infection, 
Plasmodium falciparum navigate in hostile environment and it is subjected to different stressors, 
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which can stress-damage its proteins. According to the PlasmoDB database (plasmodb.org), 
PfClpB1 and PfClpB2 are ClpB homologues in Plasmodium falciparum that are up-regulated 
during infection. 
1.5.2 Structure and biochemical properties 
The parasite is known to have two ClpB homologues: PfClpB1 and PfClpB2.  PfClpB2 
(hsp101) is localized to the parasitophorous vacuole and pfClpB1 can be found in the apicoplast 
[76], a non-photosynthetic organelle that accommodates several important metabolic pathways 
[77] and is necessary for plasmodium survival [78]. All PfClpB ATPase have the predicted two 
ATP nucleotide-binding domains with the conserved Walker A and Walker B. Different sensor 
motif can be recognized in the AAA+ domains of PfClpB ATPases. PfClpB1 (PF08_0063) is a 
123 KDa protein whereas pfClpB2 (PF11_0175) is a 103 KDa protein. 
1.5.3 PfClpB1 and PfClpB2 localization 
PfClpB1 is localized to the apicoplast, however PfClpB2 also known as Hsp101 is found 
in the parasitophous vacuole and it is part of the PTEX complex [79]. During infection, to gain 
access to the host cell cytosol, plasmodium must export its proteins through the parasitophous 
vacuole membrane. Trafficking of malaria protein across the parasitophorous vacuole membrane, 
requires a Plasmodium export element known as PEXEL [80]. Identification of the PEXEL motif 
has improved our understanding of plasmodium protein export. Some Algorithms predict that 5 
to 8% of the plasmodium genome should be exported [81]. PEXEL motif recognition occurs in 
the ER, where the fate of the proteins destined for trafficking across the parasitophous vacuole 
membrane is decided. The plasmodium translocon of exported proteins (PTEX) was discovered 
by an array of strategy combining proteomic, bioinformatics, biochemical and genetic 
methodologies. PTEX is made of five components: PfClpB2 (HSP101), PTEX150, EXP2, 
PTEX88 and TRX2.  The complex interacts with native exported protein to move them across 
the parasitophous vacuole membrane. HSP101 is predicted to oligomerize as a hexamer and 
hydrolyse ATP, which helps to unfold Plasmodium proteins [82]. EXP2 is predicted to a pore-
forming integral membrane [83]. Finally, TRX2 is believed to play a regulatory role, while 
PTEX150 and PTEX88 must probably help to recognize the malaria protein arriving in the 
parasitophous vacuole or feeding the protein into HSP101 [9]. PfClpB1 is an apicoplast protein 
with a longer N-terminal domain compared to PfClpB2 (Table 1.2 ). It has a mass of 123 kDa. 
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PfClpB1 belongs to Class I AAA+ ATPase with an extra sequence in the middle domain. This 
characteristic makes PfClpB1 a good candidate for further study. 
 
Table 1.2 The Clp proteins of P. falciparum 
(The Clp Chaperones and Proteases of the Human Malaria Parasite Plasmodium falciparum, 
Journal of Molecular Biology, Volume 404, Issue 3, 3 December 2010, Pages 456-477) 
Name Mass (kDa)a Gene IDb Gene location Protein type Localizationc 
PfClpP 43 PFC0310c Nucleus Clp protease Apicoplast 
PfClpR 28 PF14_0348 Nucleus Inactive Clp protease Apicoplastd 
PfClpB1 123 PF08_0063 Nucleus Clp ATPase Apicoplast 
PfClpB2 103 PF11_0175 Nucleus Clp ATPase Parasitophorous vacuolee 
PfClpC 156 PF14_0063 Nucleus Clp ATPase Apicoplast 
PfClpM 91 PFC10_API0060 Apicoplast Clp ATPase Apicoplast 
 
 
 
 
 
 
 
 
 
Figure 1.9 Putative model of PTEX 
This putative model of PTEX shows that the complex is formed by HSP101 (PfClpB2), PTEX 
150, PTEX88, EXP2. (That was then but this is now: malaria research in the time of an 
eradication agenda: Science 14 May 2010: Vol. 328 no. 5980 pp. 862-866) 
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1.6 Hypothesis and objectives 
Previous studies localize PfClpB1 in the apicoplast of Plasmodium falciparum.  The 
characterization of biochemical and structural properties of pfClpB1 have yet not been fully 
established. Most of what is known about PfClpB1 is the fact that it is a 123 kDa protein with an 
apicoplast targeting domain that directs the newly synthesized protein toward the apicoplast. We 
hypothesize that PfClpB1 is involved in the folding and refolding of newly synthesized and 
denatured malaria parasite proteins through its action as a ClpB homologue. During heat stress 
conditions, its chaperone activity is increased resulting in the survival of the malarial parasite. 
The main goal of this study is to produce enough soluble and fully active pfClpB1 protein in E. 
coli for thorough biochemical characterization.  First, the similarity between pfClpB1 and 
Thermus thermophilus ClpB is achieved using bioinformatics tools. Then, we study the 
biochemical properties of PfClpB1 as a homologue of E. coli ClpB. 
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Chapter 2 - Bioinformatics analysis 
2.1 Introduction 
Bioinformatics is a field of science that merge biology, statistics, mathematics and 
computer science to generate useful biological knowledge.  Bioinformatics is crucial in the field 
of genomics, proteomics and homology modeling. Homology modeling is a practical tool to 
understand the relationship between protein function and structure when an experimental model 
is not accessible. The prediction of functional residues and secondary structure is based on 
multiple sequence alignment and sequence similarity search. The function and structure 
prediction is maximized when the number of matches in the sequence alignment is increased.  
For the bioinformatics analysis, the degree of conservation of the middle domain, C 
terminal and N terminal domains between E.coli ClpB and PfClpB1 was measured with Clustal 
omega tool (http://www.ebi.ac.uk/Tools/msa/clustalo/). Homology modeling tool I-TASSER 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/) was used with Thermus thermophilus ClpB 
structure (PDB 1qvrA) to build the molecular model of PfClpB1. Pymol, the molecular 
visualization software, was used to view the predicted model. Codon analysis was carried out 
with the graphical codon usage analyser (http://gcua.schoedl.de/). Finally, SignalP 4.0 
(http://www.cbs.dtu.dk/services/SignalP/) predicted the location of a signal peptide cleavage site 
in the amino acid sequences of PfClpB1 and apicoplast targeting sequence analysis tool, 
PlasmoAP  (http://v4-4.plasmodb.org/restricted/PlasmoAPcgi.shtml), helped to identify potential 
amino acid sequences that will be part of the apicoplast targeting signal. 
The broad objective of this study was to apply bioinformatics tools, such as primary 
sequence alignments and homology modelling to identify structural features potentially of 
functional importance. Functional motifs and domains were identified by searching for 
conserved blocks within multiple sequence alignment of ClpB from plasmodium falciparum. The 
predicted three-dimensional structure was generated by Itasser computer program and visualized 
using pymol, allowing identification of domains and positions of important residues. 
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2.2 Prediction of apicoplast targeting sequence 
The signal peptide cleavage sites in amino acid sequences were detected by SignalP V4.1 
(http://www.cbs.dtu.dk/services/SignalP). The co-translational pathway is initiated after the 
signal peptide is recognized by the signal-recognition particle (SRP). That long stretch of amino 
acid that is recognized and will be cleaved by the signal peptidase. The apicoplast targeting 
sequence was detected with PlasmoAP (http://v4-4.plasmodb.org/restricted/PlasmoAPcgi.shtml) 
following these rule sets: apicoplast targeting sequence tend to be enriched for asparagines 
and/or lysines, exhibit a surplus of basic over acidic residues, and finally start with a signal 
peptide. 
2.2.1 Prediction of signal peptide cleavage site 
Prediction of the cleavage site was done by SignalP V4.1. The signal peptide is cleaved 
during post-translational processing by signal-peptidase. It was important that the signal peptide 
did not be expressed in E.coli, since it was not part of PfClpB1 protein after cleavage. The 
predicted protein sequence (Figure 2.1 ) was analyzed after specifying the exclusion of trans-
membrane regions to SignalP. The first 70 amino acids were analyzed and the cleavage of signal 
peptide site was predicted to be between position 23 and 24(Figure 2.2 ). 
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MVNSFFFCFVIIGLIYVWDITYSKKAKIFFNKNDIFSIKNTHWDIYDKKKYFFIGNNHLK 
NEESFLPEVRKDYKSQIKEYKNSTNGIIYHNNKNRLSYTINDQVNYDNNMTSGINKKRKV 
KDSSIHMNNSYEKNRNKNKFALFMSDEEYTINSDDYTEKAWEAISSLNKIGEKYDSAYVE 
AEMLLLALLNDSPDGLAERILKESGIDTQLLVQEIDDYLKKQPKMPSGFGEQKILGRTLQ 
TVLSTSKRLKKEFNDEYISIEHLLLSIISEDSKFTRPWLLKYNVNYEKVKKAVEKIRGKK 
KVTSKTPEMTYQALEKYSRDLTALARAGKLDPVIGRDNEIRRAIQILSRRTKNNPILLGD 
PGVGKTAIVEGLAIKIVQGDVPDSLKGRKLVSLDMSSLIAGAKYRGDFEERLKSILKEVQ 
DAEGQVVMFIDEIHTVVGAGAVAEGALDAGNILKPMLARGELRCIGATTVSEYRQFIEKD 
KALERRFQQILVEQPSVDETISILRGLKERYEVHHGVRILDSALVQAAVLSDRYISYRFL 
PDKAIDLIDEAASNLKIQLSSKPIQLENIEKQLIQLEMEKISILGDKQKNLFNYSSVANT 
HNNNNNSSISSNNSSSYGNAEETEATVDYTKSPNFLKKRINEKEIDRLKMIDRIMSELRK 
EQRKILDSWSTEKSYVDNIRAIKERIDVVKIEIEKAERYFDLNRAAELRFETLPDLEKQL 
KKAEENYLNDIPEKSRILKDEVTSEDIVNIVSMSTGIRLNKLLKSEKEKILNLENELHKQ 
IIGQDDAVKVVTKAVQRSRVGMNNPKRPIASLMFLGPTGVGKTELSKVLADVLFDTPEAV 
IHFDMSEYMEKHSISKLIGAAPGYVGYEQGGLLTDAVRKKPYSIILFDEIEKAHPDVYNL 
LLRVIDEGKLSDTKGNVANFRNTIIIFTSNLGSQSILDLANDPNKKEKIKEQVMKSVRET 
FRPEFYNRIDDHVIFDSLSKKELKEIANIEIRKVANRLFDKNFKITIDDAVFSYIVDKAY 
DPSFGARPLKRVIQSEIETEIAVRILDETFVENDTINISLKDQKLHFSKS 
Sequence Length: 1070 aa 
Figure 2.1 Predicted Protein Sequence of PfClpB1 
The yellow highlight represents the putative mature protein of PfClpB1 after the signal peptide 
and apicoplast targeting sequence are cleaved by post-translational processing. The green 
highlight represents the final putative signal peptide sequence. The red highlight represents the 
final putative apicoplast targeting sequence. 
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Figure 2.2 Prediction signal peptide cleavage site 
SignalP detected the presence of signal peptide cleavage site in the protein sequence. The 
cleavage site was predicted to be between position 24 and 25. 
C-score: Raw cleavage site score is trained to be high at the position immediately after the 
cleavage site (mature protein). 
S-score: Signal peptide score is trained to distinguish positions within signal peptides from 
positions in the mature part of the proteins and from proteins without signal peptides. 
Y-score: Combined cleavage site score is trained to distinguish between C-score peaks by 
choosing the one where the slope of the S-score is steep 
 
2.2.2 Apicoplast targeting sequence prediction 
The apicoplast targeting sequence was predicted by PlasmoAP (http://v4-
4.plasmodb.org/cgi-bin/plasmoap.cgi). After the prediction of the signal peptide cleavage site, 
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the next step was to find the apicoplast targeting sequence. PfClpB1 protein is localized to the 
apicoplast, but the PfClpB1 gene is localized to the nucleus. PlasmoAP outputs predicted the 
presence of an apicoplast targeting sequence in the first 150 amino acids following the signal 
peptide (Table 2.1 ). Comparison of acidic and basic amino acids content (Figure 2.3 ) of 
PfClpB1 revealed the transit peptide switch from basic to acidic at Phe 143. Change of 
acidic/basic residues ratio is one of the characteristic of bipartite apicoplast. So, we decided the 
mature protein start at Ser 145. 
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Table 2.1 Complete PlasmoAP output for query 
Only the first 150 AA have been taken into account for the analysis. The final decision is 
indicated by "++, +, 0 or -", where apicoplast-localization for a given sequence is considered. 
  ++ very likely, +  likely, 0  undecided, -  unlikely. There is a great probability for the presence 
of a signal-peptide and apicoplast targeting sequence in the first 150 amino acids. 
Criterion Value Decision 
Signal-peptide 4 of 4 tests positive ++ 
apicoplast-targeting peptide 5 of 5 tests positive ++ 
Ruleset 1 
Ratio acidic/basic residues in 
first 22 amino acids <=0.7 
0.333 Yes 
Does a KN-enriched region 
exist (40 AA with min. 9 K or 
N) with a ratio acidic/basic 
<=0.9 
0.455 Yes 
Ruleset 2 
number of acidic residues in 
first 15 amino acids (<=2)  
1 yes 
Does a KN-enriched region 
exist (40 AA with min. 9 K or 
N)? Ratio acidic/basic 
residues in this region <0.6 
0.455 yes 
Is the first charged amino acid 
basic ? 
 yes 
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Figure 2.3 Comparison of contents of acidic and basic amino acids 
The figure shows that PfClpB1 sequence shifts from basic to acidic close to Phe143. The transit 
peptide (adjacent to the signal peptide) exhibits a surplus of basic over acidic. This is a 
characteristic of bipartite apicoplast. 
2.3 Multiple sequence alignment of PfClpB1 
2.3.1 N-terminus 
Amino acid alignment of PfClpB1 and its homologues was produced to deduce conserved 
residues of the N-terminal domain. A blast search was performed in order to identify PfclpB1 
homologues.  PfClpB1 and PfClpB2 sequences were used to find identical and similar residue 
among residue. Thermus thermophilus ClpB and E. coli ClpB were used for amino acid sequence 
alignment. Alignment of the N-terminal shows highly conserved regions after the signal peptide 
and the apicoplast targeting sequence have been removed due to post-translational processing.  
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CLUSTAL O(1.2.0) multiple sequence alignment 
 
 
pfClpB2           ------------------------------------------------------------ 
pfClpb1           MVNSFFFCFVIIGLIYVWDITYSKKAKIFFNKNDIFSIKNTHWDIYDKKKYFFIGNNHLK 
ClpB_Thermus      ------------------------------------------------------------ 
ClpB_Ecoli        ------------------------------------------------------------ 
                                                                               
 
pfClpB2           ------------------------------------------------------------ 
pfClpb1           NEESFLPEVRKDYKSQIKEYKNSTNGIIYHNNKNRLSYTINDQVNYDNNMTSGINKKRKV 
ClpB_Thermus      ------------------------------------------------------------ 
ClpB_Ecoli        ------------------------------------------------------------ 
                                                                               
 
pfClpB2           ------MTRRYLKYYIFVTLLFFVQVINNVLCAPDNKQEQGKYLNRTINILNAGKNIAKS 
pfClpb1           KDSSIHMNNSYEKNRNKNKFALFM-------SDEEYTINSDDYTEKAWEAISSLNKIGEK 
ClpB_Thermus      -------------------------------------MNLERWTQAAREALAQAQVLAQR 
ClpB_Ecoli        -------------------------------------MRLDRLTNKFQLALADAQSLALG 
                                                        .     :     :   : :.   
 
pfClpB2           YGHNKLKPIHILSALAKSDYG---STLFKENNVNAANLKEYIDIALEQTRAGAPLDNKSK 
pfClpb1           YDSAYVEAEMLLLALLNDSPDGLAERILKESGIDTQLLVQEIDDYLKKQPKMPSGFGE-Q 
ClpB_Thermus      MKHQAIDLPHLWAVLLK-DERSLAWRLLEKAGADPKALKELQERELARLPKVEGAEV--G 
ClpB_Ecoli        HDNQFIEPLHLMSALLN-QEGGSVSPLLTSAGINAGQLRTDINQALNRLPQVEGTGG--D 
                       :.   :  .* : .       :: .   :   *    :  * :             
 
pfClpB2           IVNSAEVKETLALAEAAANKYKSPKVDVEHLLSGLSND--ELVNEIFNEVYLTDEAIKAI 
pfClpb1           KILGRTLQTVLSTSKRLKKEFNDEYISIEHLLLSIISEDSKFTRPWLLKYNVNYEKVKKA 
ClpB_Thermus      QYLTSRLSGALNRAEALMEELKDRYVAVDTLVLALAEATPGLPG---------LEALKGA 
ClpB_Ecoli        VQPSQDLVRVLNLCDKLAQKRGDNFISSELFVLAALESRGTLAD-ILKAAGATTANITQA 
                        :  .*  ..   ::  .  :  : :: .  .    :              :.   
 
pfClpB2           LK-RKFEKTKKDKDGKTGTLYIEQFGSNMNEKVRNGKLQGIYGRDEEIRAIIESLLRYNK 
pfClpb1           VEKIRGKKKVTSKTPEMTYQALEKYSRDLTALARAGKLDPVIGRDNEIRRAIQILSRRTK 
ClpB_Thermus      LKELRGGRTVQTEHAESTYNALEQYGIDLTRLAAEGKLDPVIGRDEEIRRVIQILLRRTK 
ClpB_Ecoli        IEQMRGGESVNDQGAEDQRQALKKYTIDLTERAEQGKLDPVIGRDEEIRRTIQVLQRRTK 
                  ::  :  ..   :  :     ::::  ::.  .  ***: : ***:***  *: * * .* 
 
pfClpB2           NSPVLVGNPGTGKTTIVEGLVYRIEKGDVPKELQGYTVISLNFRKFTSGTSYRGEFETRM 
pfClpb1           NNPILLGDPGVGKTAIVEGLAIKIVQGDVPDSLKGRKLVSLDMSSLIAGAKYRGDFEERL 
ClpB_Thermus      NNPVLIGEPGVGKTAIVEGLAQRIVKGDVPEGLKGKRIVSLQMGSLLAGAKYRGEFEERL 
ClpB_Ecoli        NNPVLIGEPGVGKTAIVEGLAQRIINGEVPEGLKGRRVLALDMGALVAGAKYRGEFEERL 
                  *.*:*:*:**.***:*****. :* :*:**. *:*  :::*::  : :*:.***:** *: 
 
pfClpB2           KNIIKELKNKKNKIILFVDEIHLLLGAGK-AEGGTDAANLLKPVLSKGEIKLIGATTIAE 
pfClpb1           KSILKEVQDAEGQVVMFIDEIHTVVGAGAVAEGALDAGNILKPMLARGELRCIGATTVSE 
ClpB_Thermus      KAVIQEVVQSQGEVILFIDELHTVVGAGK-AEGAVDAGNMLKPALARGELRLIGATTLDE 
ClpB_Ecoli        KGVLNDLAKQEGNVILFIDELHTMVGAGK-ADGAMDAGNMLKPALARGELHCVGATTLDE 
                  * ::::: . : ::::*:**:* ::***  *:*. **.*:*** *::**:: :****: * 
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pfClpB2           YRKFIESCSAFERRFEKILVEPPSVDMTVKILRSLKSKYENFYGINITDKALVAAAKISD 
pfClpb1           YRQFIEKDKALERRFQQILVEQPSVDETISILRGLKERYEVHHGVRILDSALVQAAVLSD 
ClpB_Thermus      YRE-IEKDPALERRFQPVYVDEPTVEETISILRGLKEKYEVHHGVRISDSAIIAAATLSH 
ClpB_Ecoli        YRQYIEKDAALERRFQKVFVAEPSVEDTIAILRGLKERYELHHHVQITDPAIVAAATLSH 
                  **: **.  *:****: : *  *:*: *: ***.**.:** .: :.* * *:: ** :*. 
 
pfClpB2           RFIKDRYLPDKAIDLLNKACSFLQVQLSGKPRIIDVTERDIERLSYEISTLEKDVD---- 
pfClpb1           RYISYRFLPDKAIDLIDEAASNLKIQLSSKPIQLENIEKQLIQLEMEKISILGDKQKNLF 
ClpB_Thermus      RYITERRLPDKAIDLIDEAAARLRMALESAPEEIDALERKKLQLEIEREALKKEK----- 
ClpB_Ecoli        RYIADRQLPDKAIDLIDEAASSIRMQIDSKPEELDRLDRRIIQLKLEQQALMKES----- 
                  *:*  * ********:::*.: ::: :.. *  ::  ::   :*. *  ::  :       
                   
 
 
pfClpB2           -------------------------------------------------KVSKKKYNKLI 
pfClpb1           NYSSVANTHNNNNNSSISSNNSSSYGNAEETEATVDYTKSPNFLKKRINEKEIDRLKMID 
ClpB_Thermus      ------------------------------------------------DPDSQERLKAIE 
ClpB_Ecoli        ------------------------------------------------DEASKKRLDMLN 
                                                                     . .: . :  
 
pfClpB2           KEFEEKKEQLKKYYEEYVITGERLKRKKEIEKKLNDLKE---LTQNYVYSNKE------P 
pfClpb1           RIMSELRKEQRKILDSWSTEKSYVDNIRAIKERIDVVKIEIEKAERYFDLNRAAELRFET 
ClpB_Thermus      AEIAKLTEEIAKLRAEWEREREILRKLREAQHRLDEVRREIELAERQYDLNRAAELRYGE 
ClpB_Ecoli        EELSDKERQYSELEEEWKAEKASLSGTQTIKAELEQAKIAIEQARRVGDLARMSELQYGK 
                    : .  .:  :   .:      :   :  : .::  :     :..     :         
 
pfClpB2           PIELQNSLKEAQQKYLELYKETVAYVEAKTHNAMNVDAVYQEHVSYIYLRDSGMPLGSLS 
pfClpb1           LPDLEKQLKKAEENYLNDIPEKSR---------ILKDEVTSEDIVNIVSMSTGIRLNKLL 
ClpB_Thermus      LPKLEAEVEALSEK-----LRGAR---------FVRLEVTEEDIAEIVSRWTGIPVSKLL 
ClpB_Ecoli        IPELEKQLEAATQLE----GKTMR---------LLRNKVTDAEIAEVLARWTGIPVSRMM 
                    .*: .::   :       .            :    * . .:  :    :*: :  :  
 
pfClpB2           FESSKGALKLYNSLSKSIIGNEDIIKSLSDAVVKAATGMKDPEKPIGTFLFLGPTGVGKT 
pfClpb1           KSEKEKILNLENELHKQIIGQDDAVKVVTKAVQRSRVGMNNPKRPIASLMFLGPTGVGKT 
ClpB_Thermus      EGEREKLLRLEEELHKRVVGQDEAIRAVADAIRRARAGLKDPNRPIGSFLFLGPTGVGKT 
ClpB_Ecoli        ESEREKLLRMEQELHHRVIGQNEAVDAVSNAIRRSRAGLADPNRPIGSFLFLGPTGVGKT 
                    . :  *.: :.* : ::*::: :  ::.*: :: .*: :*::**.:::********** 
 
pfClpB2           ELAKTLAIELFNSKDNLIRVNMSEFTEAHSVSKITGSPPGYVGFSDSGQLTEAVREKPHS 
pfClpb1           ELSKVLADVLFDTPEAVIHFDMSEYMEKHSISKLIGAAPGYVGYEQGGLLTDAVRKKPYS 
ClpB_Thermus      ELAKTLAATLFDTEEAMIRIDMTEYMEKHAVSRLIGAPPGYVGYEEGGQLTEAVRRRPYS 
ClpB_Ecoli        ELCKALANFMFDSDEAMVRIDMSEFMEKHSVSRLVGAPPGYVGYEEGGYLTEAVRRRPYS 
                  **.*.**  :*:: : :::.:*:*: * *::*:: *: *****:.:.* **:***.:*:* 
 
pfClpB2           VVLFDELEKAHADVFKVLLQILGDGYINDNHRRNIDFSNTIIIMTSNLGAELFKKKLFFD 
pfClpb1           IILFDEIEKAHPDVYNLLLRVIDEGKLSDTKGNVANFRNTIIIFTSNLGSQSILDLANDP 
ClpB_Thermus      VILFDEIEKAHPDVFNILLQILDDGRLTDSHGRTVDFRNTVIILTSNLGSPLILEGLQKG 
ClpB_Ecoli        VILLDEVEKAHPDVFNILLQVLDDGRLTDGQGRTVDFRNTVVIMTSNLGSDLIQERFG-E 
                  ::*:**:**** **:::**::: :* :.* : .  :* **::*:*****:  : .      
 
pfClpB2           ADNSGTPEYKRVMEDVRLSLIKKCKKVFKPEFVNRIDKIGVFEPLNKKNLHKIVALRFKK 
pfClpb1           ------NKK----EKIKEQVMKSVRETFRPEFYNRIDDHVIFDSLSKKELKEIANIEIRK 
ClpB_Thermus      ------WPY----ERIRDEVFKVLQQHFRPEFLNRLDEIVVFRPLTKEQIRQIVEIQLSY 
ClpB_Ecoli        ------LDY----AHMKELVLGVVSHNFRPEFINRIDEVVVFHPLGEQHIASIAQIQLKR 
                                 ::  ::    . *:*** **:*.  :*  * ::.: .*. :.:   
 
pfClpB2           LEKRLEEKNIQVSVSEKAIDYIIDQSYDPELGARPTLIFIESVIMTKFAIMYLKKELVDD 
pfClpb1           VANRLFDKNFKITIDDAVFSYIVDKAYDPSFGARPLKRVIQSEIETEIAVRILDETFVEN 
ClpB_Thermus      LRARLAEKRISLELTEAAKDFLAERGYDPVFGARPLRRVIQRELETPLAQKILAGEVKEG 
ClpB_Ecoli        LYKRLEERGYEIHISDEALKLLSENGYDPVYGARPLKRAIQQQIENPLAQQILSGELVPG 
                  :  ** ::  .: : : . . : :..***  ****    *:  : . :*   *   .    
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pfClpB2           MDVFVDYNSKAKNLVINLSKT- 
pfClpb1           DTINISLKDQKLHFSKS----- 
ClpB_Thermus      DRVQVDVGPAGLVFAVPARVEA 
ClpB_Ecoli        KVIRLEVNEDRIVAVQ------ 
                    : :.               
 
 
 
Figure 2.4 Multiple sequence alignment of the N-terminal domains, Middle domain and C-
termini of PfClpB1 homologues. 
The Walker A and the Walker B are highly conserved in the AAA domains of The PfClpB1. The 
main difference is found in the N-terminal and the Middle domain. Sequence alignment was 
performed using Clustal Omega.  Identical amino acid residues are marked with “*” symbol and 
“.”  and “:” represent the degree of similarity. 
 
2.3.2 Middle domain 
The middle domain is responsible for the species specific cooperation with the HSP70 
system. The PfClpB1 middle domain has 52 extra amino acid residues (Figure 2.4 ) that are not 
present in Thermus thermophilus ClpB and E. coli ClpB. The function of that specific sequence 
is still unknown. 
2.3.3 C-terminus 
The C-terminal domain is required for oligomerization and it is called the sensor domain. 
The C-terminal is highly conserved in PfclpB1, which confirm its importance during protein 
disaggregation. The sequence alignment was performed with Thermus thermophilus ClpB and E. 
coli ClpB. PfClpB1 and PfClpB2 show some dissimilarity in the C-terminal domain. 
 
2.4 Modeling and DNA analysis of PfClpB1 
2.4.1 Homology modeling of PfClpB1 
I-TASSER was used to predict PfClpB1 structure using Thermus Thermophilus ClpB 
(PDB 1qvrA) as the main template. PfClpB1 showed conserved structural similarity in the N-
terminal, C-terminal, Middle domain and the Nucleotide binding domains. Thermus 
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Thermophilus ClpB was used for homology modeling because its structure was known and it was 
a close homologue of PfClpB1. Pymol was used to model the multiple domains of PfClpB1. The 
homology modeling was carried on after removing the putative signal peptide signal and the 
apicoplast targeting sequence since those must be remove during post-translational processing. 
Comparison of the two models (PfClpB1 and TClpB) showed that the domains were 
significantly similar (Figure 2.5 ) except mainly for the middle domain where some extra amino 
acid residues were really specific for PfClpB1 and could not be properly aligned.  
 
Figure 2.5 Homology modeling of the predicted Tertiary structure of PfClpB1. 
Thermus  Thermophilus ClpB (1qvrA) was used as a template for the modeling of PfClpB1. The 
N-terminal α/β subdomain (on the bottom) and the C-terminal α-helical subdomain (at the top) 
are shown in the figure respectively. The N-terminal domain, C-terminal domain, the NBD1, and 
NBD2 are conserved. The middle domain was represented with different colors. The red helix 
represents the extra amino acid in the middle domain whose function is still unknown in 
pfClpB1. The model was generated with I-TASSER and visualized using pymol. 
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2.4.2 Codon analysis 
The relative adaptiveness of PfClpB1 in E. coli was analyzed with the graphical codon 
usage analyzer (http://gcua.schoedl.de/). The Genscript tools (http://www.genscript.com/cgi-
bin/tools/rare_codon_analysis) were used to visualize the codon usage and GC content of 
PfClpB1 gene. Finally, the occurrence of the rare codon in PfClpb1 was mapped with Rare 
Codon Calculator (http://nihserver.mbi.ucla.edu/RACC/). The distribution of codon usage 
frequency along the length of PfClpB1 (Figure 2.7 ) showed that the CG content was low and 
would be problematic during protein expression. The presence of rare codon (Figure 2.9 ) 
confirmed the need for a special strain of E.coli. 
 30 
 
Figure 2.6 Graph shows the relative adaptiveness of PfClpB1. 
The relative adaptiveness was analyzed by comparing the nucleotide sequence of PfClpB1 with 
the codon table of E.coli. The graph shows the percentage of adaptiveness of every codon of 
PfClpB1 expressed in E.Coli. The gray and black bars indicate PfClpB1 and E.coli codon table 
respectively. 
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Figure 2.7 The distribution of codon usage frequency along the length of PfClpB1 
expressed in E.coli. 
The distribution of codon usage frequency was made using the genscript rare codon analysis 
tools. The Codon Adaptation Index (CAI) was 0.62 which was below the level required for good 
protein expression. 
 
 
 
 
Figure 2.8 The GC content of PfClpB1. 
The Average GC content was 27.71%. Any peaks outside 30% to 70% will adversely affect 
transcriptional and translational efficiency. 
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atg gtt aat agt ttt ttt ttt tgt ttt gtg ATA att ggt ctt att tat gta tgg gac 
atc acg tac agt aaa aaa gct aaa ATA ttt ttt aat aaa aat gat atc ttt 
agt ATA aaa aat acg cac tgg gat att tat gat aag aag aaa tat ttt ttt att gga 
aat aat cat tta aaa aat gaa gaa agt ttt tta cca gaa gta AGA aag gat tat aaa 
tca caa ATA aaa gaa tat aag aat tca acg aat ggt att ATA tat cat aat aat aaa 
aac AGA tta agt tat aca ATA aat gat caa gta aat tat gat aat aat atg aca agt 
ggt att aat aaa aaa AGA aaa gtt aaa gat agt agt ATA cac atg aat aat tct tat 
gaa aaa aat AGA aac aaa aat aaa ttt gct tta ttt atg agt gat gaa gaa tat acc 
att aat tca gat gat tat acc gaa aaa gct tgg gaa gct att agc tcc tta aat aaa 
att gga gaa aaa tat gat tcg gca tat gta gaa gct gaa atg tta tta tta 
gct CTA CTA aat gat tca CCC gat ggt tta gct gaa AGA ATA tta aaa gaa agt 
ggtATA gat acc caa tta tta gtt caa gaa att gat gat tat tta aaa aaa caa cct 
aag atg cct agt ggt ttt gga gaa cag aaa ATA tta ggt AGA act tta caa act gta 
tta agt act agt aaa AGA tta aaa aaa gaa ttt aat gat gaa tat att tcc ATA gaa 
cac CTA tta CTA agt atc att tca gaa gat tct aaa ttt act AGA CCC tgg tta tta 
aaa tat aat gta aat tat gaa aaa gta aaa aaa gct gta gaa aaa att CGA gga aaa 
aaa aaa gtt act tct aaa aca cca gaa atg act tat caa gct CTA gaa aaa tat 
agt AGA gat CTA aca gct ttg gca AGA gca gga aaa tta gat cct 
gtt ATA ggt AGA gat aat gaa att AGA AGA gcc ATA caa att tta tcc AGA AGA act 
aaa aat aat cct atc tta tta gga gat cct ggt gtt ggg aaa aca gct att gtt gaa 
ggg tta gcc ATA aaa atc gta caa gga gat gta cct gac tca tta aaa gga AGG aaa 
tta gta tct tta gat atg tct tct ctt ATA gct ggt gca aaa tat AGA ggt gat ttt 
gaa gaaAGG CTA aaa tca att ctg aaa gaa gta caa gat gct gaa ggt caa gtt gtt 
atg ttt ATA gat gaa atc cat act gtt gtg gga gct gga gcg gtc gca gaa ggt gca 
tta gat gct ggt aatATA tta aaa cct atg tta gct AGA ggt gaa tta cgt tgt att 
ggt gct acg acg gtt agt gaa tat AGA caa ttt ATA gaa aag gat aaa gca tta 
gaa AGA AGA ttt caa caa att ctt gtt gaa caa cca agt gtt gat gaa act att 
agt ATA tta AGA ggt CTA aaa gaa AGA tat gaa gtt cat cat ggt gta cgt ATA tta 
gat tct gca tta gta caa gct gct gtt tta tca gat cgt tat att agt tat AGA ttc 
tta cca gat aaa gcg att gat ctt att gac gaa gct gca tct aat ctt 
aaa ATA caa CTA tct agt aaa cct att caa tta gaa aat ATA gaa aaa caa 
ctt ATAcaa tta gaa atg gaa aaa ATA tcc ATA tta gga gat aaa caa aag 
aat CTA ttt aat tat tct agt gta gct aac aca cac aat aat aat aat aat agt agt 
att agt agc aat aac tcg tca tca tat ggt aac gct gaa gaa act gaa gca act gtt 
gat tat act aaa agc CCC aat ttt tta aaa aaa AGA att aat gaa aaa gaa att 
gat AGA tta aaa atg atc gat CGA atc atg agc gaa tta AGA aaa gaa caa AGA aaa 
atc CTA gat tct tgg tcc acc gaa aaa agc tat gta gat aat atc AGA gct att aaa 
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gaa AGA ATA gat gtt gtt aaa ATA gaa att gaa aaa gct gaaAGA tat ttt gat tta 
aat AGA gca gct gaa ttg AGA ttt gaa aca tta cct gat tta gaa aaa caa tta aaa 
aaa gca gaa gaa aat tat CTA aat gat atc cct gaa aaa agt AGA ATA tta aaa gat 
gaa gtt aca agt gaa gat att gtt aat att gta agt atg tct acc ggt atc AGA tta 
aat aaa tta CTA aaa tct gaa aaa gaa aaa ATA ctt aat ctt gaa aat gaa tta cat 
aaa caa att atc ggt caa gat gat gcc gta aaa gtt gta acc aaa gct gtt 
caa AGA tct AGG gtt gga atg aat aac cct aaa AGA cca ATA gca tct tta atg ttt 
tta gga cca aca gga gta gga aaa acg gaa tta tct aag gta ttg gca gat gta tta 
ttt gac aca cca gaa gca gta att cat ttt gat atg tct gaa tat atg gag aag cat 
tca att agt aaa tta ATA ggt gcc gca cca ggt tat gtg gga tat gaa caa gga gga 
tta tta aca gat gca gta cgt aaa aaa cca tat tct atc att tta ttt gat 
gaa ATA gaa aaa gca cat cct gat gta tat aat tta tta ttaAGA gtt ATA gat gag 
gga aaa tta tct gat acc aaa gga aat gta gct aat ttt AGA aat aca att 
att ATA ttt aca tcc aat tta gga agt caa agt ATA CTA gat CTA gct aat gat cca 
aat aaa aaa gaa aaa atc aaa gaa cag gta atg aaa tca gtg AGA gaa aca 
ttt AGA cct gaa ttt tat aac AGA att gat gat cat gtt ATA ttt gat agc tta tca 
aaa aaa gaa tta aaa gaa att gca aat att gaa att AGA aaa gta gct aat 
cgt CTA ttt gat aaa aat ttt aaa ATA act ATA gac gat gct gtc ttt tca 
tat ATA gta gat aaa gcc tat gat cct tct ttt ggt gct AGA cct ctt 
aaa AGA gtt ATA caa tct gaa ATA gaa acg gaa att gct gta AGA ATA tta gat gaa 
acc ttt gta gaa aat gat act att aat ATA tct ctc aag gat cag aag ttg cac ttt 
tca aaa agt taa  
 
Figure 2.9  The occurrence of rare codons in PfClpB1 
Red = rare Arg codons AGG, AGA, CGA./ Green = rare Leu codon CTA./ Blue = rare Ile 
codon ATA / Orange = rare Pro codon CCC. The occurrence of rare codons was mapped with 
Rare Codon Calcμl ator (http://nihserver.mbi.ucla.edu/RACC/). 
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Chapter 3 - Expression and purification of PfClpB1 
3.1 Cloning 
Subcloning was performed by moving the PfClpB1 gene from the parental vector 
P15TV-L, a gift from Dr. Raymond Hui of the University of Toronto, to the destination vector 
pET28a(+) (Figure 3.1 ), using PfuUltra II DNA polymerase (Agilent Technologies) for 
amplification.  Codons for arginine (AGG or AGA), glycine (GGA) and isoleucine (AUA), are 
found to be rarely used and have a damaging effect on protein expression in E.Coli (Table 3.1 ).  
P. falciparum contains an A-T rich genome, consequently causing rare codon usage in E. coli as 
confirmed by codon analysis. A special strain of E.coli such as Rosetta strain DE3 (Novagen) 
was used to provide rare tRNAs for Leucine, Isoleucine, Arginine, Glycine, Proline to enhance 
protein expression. The setup for the PCR reaction was conducted with the following protocol 
for PfuUltra II DNA Polymerase (Agilent Technologies). 2.0 μl PfClpB1 template (100 ng/μl ) 
was used with 0.8 μl dNTP mix (25 mM each dNTP), 10.0 μl of 10× PfuUltra II reaction buffer, 
200 ng of each  designed forward and reverse primer, 2.0 μl of PfuUltra HF DNA polymerase 
(2.5 U/μl) , finally the volume was brought to 100μl with distilled water (dH2O) .  The PCR 
cycling parameters for PfuUltra II DNA Polymerase were performed as follows: 95°C 2 mins, 
followed by 30 cycles: 30 seconds at 95°C, 30 seconds at 55°C, and 4 mins at 72°C in each 
cycle. Then, the amplified products were elongated for an additional 15 mins at 72°C. PCR 
products were gel purified with QIAEX II Gel Extraction Kit (Qiagen). UV absorbance at 260 
nm was used to find the DNA concentration. Then PCR products and pET28a(+) were digested 
with restriction enzymes XhoI and NheI from New England Biolabs at 37°C for 4 h, and purified 
from agarose gels using QIAEX II Gel Extraction Kit (Qiagen). The digested vector and PCR 
products were ligated with Rapid DNA Ligation Kit (Roche) at 16°C overnight. Rosetta2 (DE3) 
cells were transformed with the ligated vector. The transformed colonies were selected against 
chloramphenicol (Rosetta 2 (DE3)) and kanamycin (pET28a(+)). DNA sequencing was 
performed at the Plant Pathology sequencing facility to check the accuracy of our transformation.  
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 Primers used for amplification of the PfClpB1 with the restriction site for NheI and 
XhoI. 
Forward primer:  
5’ CGCGCTAGCAGTGATGAAGAATATACCATT 3’ (NheI) 
Reverse primer: 
5’ CGCGCACTCGAGTTAACTTTTTGAAAAGTGCAA 3’ (XhoI) 
 
Table 3.1 Rarely used codons in E.coli. 
Lee, S.F., Li, Y.J., and Halperin, S.A. (2009). “Overcoming codon-usage bias in 
heterologous protein expression in Streptococcus gordonii.”  Microbiology 155:3581-3588. 
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Figure 3.1 Novagen pET-28a(+) 
Plasmid map pET-28a(+) showing restriction sites of XhoI and NheI 
 
3.2 Protein expression 
The pfClpB1 coding sequence (amino acids Ser145-Ser1070) was cloned into pET28 
vector with a His-tag on the N-terminus. The protein expression was started by inoculating a 
single colony holding the pET28vector with pfClpB1 gene into 50 ml LB containing 50ug/mL 
chloramphenicol and 50ug/mL kanamycin. The cultures were incubated overnight at 37°C with 
shaking at 225 rpm. Afterward, a 1:20 dilution of the overnight cultures was poured into 1000 ml 
fresh LB and was grown at the same conditions with similar concentration of chloramphenicol 
and kanamycin until an OD600 reading of 0.5. Finally, protein expression was induced at 37°C 
for 2 h with 0.4 mM IPTG. SDS-page analysis was conducted (Figure 3.3 ) to detect the 
expression of a 107 KDA protein. MS analysis would be done along the way to confirm that our 
protein is PfClpB1. 
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A 
MGSSHHHHHHSSGRENLYFQGASDEEYTINSDDYTEKAWEAISSLNKIGEKYDSAYVEAEMLLLA
LLNDSPDGLAERILKESGIDTQLLVQEIDDYLKKQPKMPSGFGEQKILGRTLQTVLSTSKRLKKEFNDEYISI
EHLLLSIISEDSKFTRPWLLKYNVNYEKVKKAVEKIRGKKKVTSKTPEMTYQALEKYSRDLTALARAGKLD
PVIGRDNEIRRAIQILSRRTKNNPILLGDPGVGKTAIVEGLAIKIVQGDVPDSLKGRKLVSLDMSSLIAGAKY
RGDFEERLKSILKEVQDAEGQVVMFIDEIHTVVGAGAVAEGALDAGNILKPMLARGELRCIGATTVSEYRQ
FIEKDKALERRFQQILVEQPSVDETISILRGLKERYEVHHGVRILDSALVQAAVLSDRYISYRFLPDKAIDLID
EAASNLKIQLSSKPIQLENIEKQLIQLEMEKISILGDKQKNLFNYSSVANTHNNNNNSSISSNNSSSYGNAEET
EATVDYTKSPNFLKKRINEKEIDRLKMIDRIMSELRKEQRKILDSWSTEKSYVDNIRAIKERIDVVKIEIEKAE
RYFDLNRAAELRFETLPDLEKQLKKAEENYLNDIPEKSRILKDEVTSEDIVNIVSMSTGIRLNKLLKSEKEKI
LNLENELHKQIIGQDDAVKVVTKAVQRSRVGMNNPKRPIASLMFLGPTGVGKTELSKVLADVLFDTPEAVI
HFDMSEYMEKHSISKLIGAAPGYVGYEQGGLLTDAVRKKPYSIILFDEIEKAHPDVYNLLLRVIDEGKLSDT
KGNVANFRNTIIIFTSNLGSQSILDLANDPNKKEKIKEQVMKSVRETFRPEFYNRIDDHVIFDSLSKKELKEIA
NIEIRKVANRLFDKNFKITIDDAVFSYIVDKAYDPSFGARPLKRVIQSEIETEIAVRILDETFVENDTINISLKD
QKLHFSKS 
 
Figure 3.2 The amino acid sequence of 6×His- tag pfClpB1 after cleavage of the signal 
peptide and apicoplast targeting sequence 
The polyhistidine region is underlined. The target protein is marked as red 
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E. coli lysate 1 E. coli lysate 2 E. coli lysate 3 E. coli lysate 4 
 
 
Figure 3.3  SDS gel electrophoresis analysis of PfClpB1 after protein expression. 
M: Molecular mass ladder. +: IPTG induction. -: No induction. The red arrow indicates the band 
of the putative PfClpB1protein with a molecular weight of 107 kDa. Shown is the protein 
expression of 4 independent E. coli cultures either non-induced (-) or induced with IPTG (+) 
after 2 hours. 
3.3 Solubility test 
Isolation of the cell pellets for solubility test was initiated by centrifuging at 4000 x g for 
20 min at 4°C, and the mass of the cells was weighted. Next, 4 ml/g of ice-cold lysis buffer (300 
mM NaCl, 10 mM imidazole in 50 mM sodium phosphate buffer, pH 8.0) was added to the 
pellets.  Sonication on ice for 25 ×15 seconds with a 10 sec cooling between each burst was used 
to disrupt the cells. 100 μL lysates was collected after sonication for centrifugation at 14,000 × g 
for 5 min at 4°C. Then, the insoluble fraction was taken out by solubilizing the pellets in 100 μL 
cold lysis buffers (300 mM NaCl, 10 mM imidazole in 50 mM sodium phosphate buffer, pH 
8.0). The remaining lysates were centrifuged at 4000 × g for 20 min at 4°C. For the solubility 
test, 100 μL supernatant as soluble fraction was collected. The rest of soluble fractions were 
saved for purification. Finally, SDS-Page followed by coomassie blue staining was performed on 
15 μL aliquots of each cellular fraction. 
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3.4 Purification of His3tagged PfClpB1 
The soluble fraction of pfClpB1 was purified under native conditions by nickel- affinity 
Chromatography (Ni2+-NTA).  Pre-equilibrated Ni-NTA resin (Invitrogen) with the supernatant 
was mixed overnight at 4°C. The mixture was then poured into a 1.5 cm diameter column and 
the flow-through was saved. After washing, the pfClpB1 proteins were eluted with 250 mM 
imidazole. Purified proteins fractions were analyzed with SDS-PAGE (Figure 3.4 ), followed by 
coomassie blue staining. Finally, the concentration of purified pfClpB1 proteins was measured 
spectrophotometrically and reported in monomer units. 
 
 
Figure 3.4 SDS gel electrophoresis analysis of purification of 6×His-tagged 
PfClpB1 by using Ni-NTA affinity chromatography under native conditions. 
Each lane represents different protein fractions collected overtime. The flow-through was saved 
for analysis. The elution fraction was collected with an elution buffer from a purification kit. 
M: molecular mass ladders. The red arrow: The band of PfClpB1.  F1-F3: Flow-through.  W1-
W9: wash.  E1-E4: Elution. 
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3.5 Gel filtration 
Gel filtration was used for further purification of the PfClpB1 proteins. A Superdex 200® 
(GE LifeSciences) was equilibrated with 50 mM Tris-HCl PH 7.5, 1mM EDTA, 1mM DTT, 20 
mM MgCl2, 0.1 M KCl, at a flow rate of 2 mL/min. Elution was carried with 250 mM imidazole. 
The partially purified pfClpB1 from Ni-NTA filtration was loaded into the system at a rate of 0.1 
mL/min. All collected samples were analyzed with 10% SDS-PAGE to figure out the pfClpB1 
fractions with the least amount of contaminants. The resulting gel (Figure 3.5 ) revealed a protein 
with a molecular weight of 107Kda.  
 
 
Figure 3.5 SDS gel electrophoresis analysis of Gel filtration 
M: Molecular mass ladder.  
Lanes 1, 2, 3, 4, 5 represents fractions containing PfClpB1 protein after gel filtration purification.  
The red arrow indicates the band of PfClpB1. 
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3.6 Mass spectrometry 
The purified proteins were heated at 95 °C for 6min and treated with 2 x SDS loading 
buffer made of SDS and β-mercaptoethanol. The sample was loaded with 10% SDS-PAGE, and 
run on constant voltage of 200 V for approximately 30 min. The Electrophoresis buffer was 
made of Tris-glycine-SDS buffer. The gels were then stained with coomassie blue R-250 for 60 
min and destained with 40% (v/v) methanol and 10% (v/v) acetic acid.  Finally, MS analysis of 
tryptic peptides (Figure 3.6) was performed by KSU Biotechnology/Proteomics facility to 
confirm that the purified protein was a match to PfClpB1 peptide after gel purification.  
 
 
1   MGSSHHHHHH SSGLVPRGSH MASDEEYTIN SDDYTEKAWE AISSLNKIGE 
51  KYDSAYVEAE MLLLALLNDS PDGLAERILK ESGIDTQLLV QEIDDYLKKQ 
101 PKMPSGFGEQ KILGRTLQTV LSTSKRLKKE FNDEYISIEH LLLSIISEDS 
151 KFTRPWLLKY NVNYEKVKKA VEKIRGKKKV TSKTPEMTYQ ALEKYSRDLT 
201 ALARAGKLDP VIGRDNEIRR AIQILSRRTK NNPILLGDPG VGKTAIVEGL 
251 AIKIVQGDVP DSLKGRKLVS LDMSSLIAGA KYRGDFEERL KSILKEVQDA 
301 EGQVVMFIDE IHTVVGAGAV AEGALDAGNI LKPMLARGEL RCIGATTVSE 
351 YRQFIEKDKA LERRFQQILV EQPSVDETIS ILRGLKERYE VHHGVRILDS 
401 ALVQAAVLSD RYISYRFLPD KAIDLIDEAA SNLKIQLSSK PIQLENIEKQ 
451 LIQLEMEKIS ILGDKQKNLF NYSSVANTHN NNNNSSISSN NSSSYGNAEE 
501 TEATVDYTKS PNFLKKRINE KEIDRLKMID RIMSELRKEQ RKILDSWSTE 
551 KSYVDNIRAI KERIDVVKIE IEKAERYFDL NRAAELRFET LPDLEKQLKK 
601 AEENYLNDIP EKSRILKDEV TSEDIVNIVS MSTGIRLNKL LKSEKEKILN 
651 LENELHKQII GQDDAVKVVT KAVQRSRVGM NNPKRPIASL MFLGPTGVGK 
701 TELSKVLADV LFDTPEAVIH FDMSEYMEKH SISKLIGAAP GYVGYEQGGL 
751 LTDAVRKKPY SIILFDEIEK AHPDVYNLLL RVIDEGKLSD TKGNVANFRN 
801 TIIIFTSNLG SQSILDLAND PNKKEKIKEQ VMKSVRETFR PEFYNRIDDH 
851 VIFDSLSKKE LKEIANIEIR KVANRLFDKN FKITIDDAVF SYIVDKAYDP 
901 SFGARPLKRV IQSEIETEIA VRILDETFVE NDTINISLKD QKLHFSKS 
Figure 3.6 Mass spectrometry of purified PfClpB1 
The peptides detected by MS analysis are shown in red. 
3.7 Conclusion 
A purified form of mature recombinant PfClpB1was produced in Rosetta BL21(DE3) 
strain of E. coli. Rosetta BL21(DE3) provides tRNAs for the rare codons found in the PfClpB1. 
The mature PfClpB1 is without the bipartite N-terminal targeting sequence. 
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Chapter 4 - In vitro Characterization of PfClpB1: Methods 
E. coli ClpB has been the object of extensive research regarding its biochemical 
properties. ClpB is up-regulated and can reactivate aggregated proteins during cellular stress. 
Better knowledge about the mechanism of aggregate related diseases has been established 
because of our understanding of ClpB function.  During infection, ClpB is up-regulated in many 
pathogenic bacteria and helps to overcome stress from the immune system of the host. Previous 
studies confirm the need of ClpB during the pathogenic stage. Since, ClpB exists in bacteria, but 
not in humans, it is a good target for therapeutic drugs. Sequence alignment of PfClpB1 shows 
two conserved nucleotide binding domains in PfClpB1, containing the Walker A and Walker B 
motifs. Sequence identity between PfClpB1 and E. coli ClpB is also quite high, but the middle 
domain carries extra amino acid residues.  In this chapter, we studied the oligomeric structure of 
PfClpB1, ATPase activity and chaperone activity. 
4.1 ATPase activity 
Analysis of the ATPase activity of PfClpB1 was performed with a Malachite green 
phosphate assay.  The assay dye was prepared in a 3:1 mixture of 0.045% malachite green and 
4.2% ammonium molydate in 4N HCL. 6 ml of malachite green (0.045%) was added to 2ml 
ammonium molydate in 4N HCL (4.2%) and finally 150 μl of 10% tween solution was used to 
complete the mixture. The assay dye mixture was equilibrated for 30 minutes before usage. 34% 
sodium citrate was also prepared. From 10mM of phosphate stock solution, a 2.5 mM phosphate 
solution was prepared by adding 20 μl of the stock solution to 60 μl of distilled water. The 2.5 
mM phosphate solution was used to build the standard curve. PfClpB1 and ClpB1 were 
incubated in assay buffer (100 mM Tris/HCl pH 8.0, 5 mM ATP, 1 mM DTT, 10 mM MgCl2, 
and 1 mM EDTA) at 37 °C for 30 min without or with 0.1 mg/ml α-casein or 0.04 mg/ml poly-
lysine. The concentration of ClpB and pfClpB1 were 0.1 mg/ml in the presence of α-casein and 
poly-lysine, 1 mg/ml for the basal activity. For the blank 45 μl  buffer assay was mixed with 5 μl  
buffer B (Buffer B: 50 mM Tris pH 7.5, 0.1 M KCL, 0.1 M EDTA and 1 M DTT was used 
during gel filtration for pfClpB1 extraction) and also incubated at 37 °C for 30 min. After 
incubation, 800 μl of dye solution was added and this was followed one minute later with 100 μl 
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of 34% sodium citrate. The ATPase activity was measured with a spectrophotometer at 660 nm 
as described before [15]. 
4.2 Sedimentation velocity 
A Beckman Xl-I analytical ultracentrifuge with 2-channel analytical cells was used for 
the sedimentation experiment. The data were analyzed with the software included with the 
instrument using a time-derivative approach. The sedimentation velocity analysis of pfClpB1 
was performed at 49,000 rpm and 20 °C with absorption profiles measured at 242 nm after 0.7-
mg/ml protein sample was dialyzed in 50 mM Tris/HCL pH 7.5, 0.2 M KCl, 20 mM MgCl2, 1 
mM EDTA, 2 mM β-mercaptoethanol. Before sedimentation velocity, protein dialysis was 
performed to exchange buffer B with buffer for sedimentation velocity. Finally, 2 mM ATPˠS 
[adenosine-50-(ˠ-thio)-triphosphate] was added to the sample and ultracentrifugation was 
performed at 42,000 rpm with absorption profiles measured at 291 nm.  
 
 
Table 4.1 Buffer for sedimentation velocity 
50 mM Tris/HCL pH 7.5 0.1 L of 1 M Tris 
0.2 M KCl 0.2 L of 1 M KCL 
20 mM MgCl2 0.02 L of 1M MgCl2 
1 mM EDTA 0.02 L of 0.1 M EDTA 
2 mM β-mercaptoethanol 0.31 mL of 13M β-mercaptoethanol 
dH2O Water to 2 L 
 
4.3 Protein reactivation assay 
Next we tested the chaperone activity of pfClpB1. 226 μM Luciferase stock from 
Promega was used. The recombinant  firefly luciferase was diluted 300-fold into buffer 1 ( 50 
mM Tris pH 7.5, 120 mM KCL, 10 mM MgCl2, 1 mM EDTA, 6 mM ATP and 10 mM DTT ) 
and incubated at 45 degree Celsius for 12 minutes to denature the protein. Then, the denatured 
firefly luciferase (0.75 μM) was diluted 20-fold with  buffer 1 containing 2 μM E. coli ClpB or 
pfClpB1, 6 mM ATP, 1 μM DnaK or human Hsp70, 1 μM DnaJ or human Hdj1 , and 0.5 μM 
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GrpE. Denatured firefly luciferase diluted with buffer 1 without the chaperones was used as a 
negative control. To measure firefly luciferase reactivation, aliquots from each reaction was 
pipetted into a 96 well plates followed by measurement with a luminometer. 
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Chapter 5 - In vitro Characterization of PfClpB1: Results and 
Discussion 
PfClpB1 is a good target for the development of therapeutic drug because of its presence 
in the apicoplast, which is an organelle that is absent in mammalian. Adequate expression of 
PfClpB1 protein was the initial step for the biochemical characterization of pfClpB1. 
Bioinformatics analysis 
The tRNAs of each organism determine the codon bias of that population. Codon bias 
varies among different organisms. To determine how codon usage affects protein expression in 
PfClpB1, Graphical Codon Usage Analyzer was used. Some of pfClpB1 codons have low 
relative adaptiveness compared to E.Coli codons. Bioinformatics analysis reveals a low GC 
content in PfClpB1 and confirms the need for a special host system such as the Rosetta (DE3) 
Competent Cells to enhance protein production during expression. 
The prediction of a signal peptide and an apicoplast targeting sequence suggest that the 
mature protein will be shorter. Since we do not fully understand the apicoplast cleavage mode of 
action, we propose that the N-terminus of the mature protein is close to Phe143. PfClpB1 
sequence shifts from basic to acidic close to Phe143: a characteristic of transit peptide, and then 
sequence similarity between E. coli ClpB and PfClpB1 is visible in the region following that 
residue. 
Multiple sequence alignment of PfClpB1 to Thermus thermophilus ClpB and E. coli 
ClpB confirms that PfClpB1 shares a lot of similarities with the member of the ClpB families. 
The N-terminal shows highly conserved regions after the signal peptide and the apicoplast 
targeting sequence. The C-terminal and the nucleotide binding domains are also well conserved. 
Multiple sequence analysis predicts that PfClpB1 would form an oligomer which is a 
characteristic of the AAA+ superfamily protein ATPase. 
These first analyses are used as a premise to predict the final form of PfClpB1 after 
protein expression. This is important because we want to express the protein in its final form in 
E. coli. Homology modeling and multiple sequence alignment suggest that the mature PfClpB1 
protein structure is similar to Thermus thermophilus ClpB. However, the 52 extra middle domain 
amino acids of PfClpB1 seem to be a hard fit in the predicted structure.  The middle domain is 
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responsible for the specificity and binding with the KJE chaperone system of E.coli ClpB. 
Consequently, the 52 extra amino acid residues inserted in the middle domain could interfere 
with KJE chaperone cooperation. 
Expression and purification of pfClpB1 in Rosetta strain of E.Coli 
Expression of plasmodium genes is complex in E.Coli because of the codon bias and the 
presence of A-T rich genome. There are 2 ways in which full-length protein may be expressed: 
(i) by changing the rare codons of the Plasmodium gene to match E. coli through mutagenesis, or 
(ii) To engineer an E. coli strain with a plasmid that produces tRNAs that spots the rare codons. 
E.coli Rosetta (DE3) strain was used because it provides the tRNAs for the rare codons. The 
original Plasmid p15TV-L was replaced by pet28a (+) because we needed to introduce a 6xHis-
tag codons on the N-terminal. DNA sequencing revealed that the insert in p15TV-L was a copy 
of pfClpB1 gene. Next, we purified the protein by Ni2+-affinity chromatography under native 
condition. The results show that the target protein efficiently binds to the column with a few non-
specific bindings. The identity of pfClpB1 was confirmed by MS analysis. Then we used gel 
filtration for further purification. Overall, the results reveal that it is inherently hard to purify 
PfClpB1 protein in large quantity in its native form. However the protein expression level was 
enough for our biochemical studies. 
ATP Hydrolysis of PfClpB1 
Basal ATP hydrolysis of PfClpB1 was found to be similar to that of E.Coli ClpB. Poly-
lysine and α-casein was found to stimulate PfClpB1, but at a lower rate than ClpB. These results 
indicate that PfClpB1 is involved in disaggregation activity. Work on the DnaJ proteins of 
Plasmodium falciparum (Pfj 1-4) would have aided to reveal to what extent Pfjs stimulates the 
ATPase activity of PfClpB1. 
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Figure 5.1 ATPase activity of PfClpB1 and E. coli ClpB in the presence of 
polylysine 
The initial rate of hydrolysis of ATP catalyzed by PfClpB or EcClpB was determined 
at 37 degree Celsuis for basal activity and with 0.04 mg/ml poly-lysine. The average 
values from four separate experiments are shown with the standard deviations. 
1: E.Coli ClpB. 2: E.Coli ClpB + polylysine. 3: PfClpB1. 4: PfClpB1 + + poly-
lysine. 
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Sedimentation Velocity 
 
The oligomerization of PfClpB1 was tested by sedimentation velocity. In the absence of 
nucleotide PfClpB1 stayed mainly monomeric. When ATPγS was provided, distributions of the 
sedimentation coefficients g(s*) shifted from 4.5S (monomeric) to 10S and 16.5S (oligomeric), 
indicating oligomers were the main component in the solution (Figure 4.1 and figure 4.2). Thus, 
it can be deducted that the oligomerization of PfClpB1occurs, but it is very dynamic process 
because the addiction of nucleotide pull it toward the oligomeric form. The data also suggests 
that there a two oligomeric form of PfClpB1. All those findings are consistent with the 
characteristic of members in the AAA+ family. 
Figure 5. 2  ATPase activity of PfClpB1 and E. coli ClpB in the 
presence of α-casein 
The initial rate of hydrolysis of ATP catalyzed by PfClpB or EcClpB was 
determined at 37 degree Celsuis for basal activity and with 0.2 mg/ml α-
casein. The average values from four separate experiments are shown with 
the standard deviations. 
1: E.Coli ClpB. 2: E.Coli ClpB + α-casein. 3: PfClpB1. 4: PfClpB1 + α-
casein. 
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Figure 5.3 Sedimentation velocity analysis of pfClpB1. 
Ultracentrifugation was performed at 49,000 rpm and 20 °C for the 0.7 mg/ml protein 
samples in 50 mM Tris/HCL pH 7.5, 0.2 M KCl, 20 mM MgCl2, 1 mM EDTA, 2 mM 
β-mercaptoethanol. The apparent sedimentation coefficient distributions g(s*) are 
shown. 
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Protein reactivation assay 
The mechanism of aggregate reactivation by pfClpB1 machinery in the presence of 
luciferase was studied. E. coli ClpB shows an increase in aggregate reactivation activity in the 
presence of the KJE chaperone system as expected. However pfClpB1 shows a decrease in 
aggregate reactivation activity in the presence of the KJE chaperone system. This can be 
explained by the extra sequence of amino acids in the middle domain of pfClpB1 which affect 
the specificity and binding with the KJE chaperone system. The results are not surprising, but 
support the important role played by the middle domain. Furthermore, the experiment also 
suggests that PfClpB1 binds with the KJE chaperone system, but it seems like there are 
Figure 5.4 Sedimentation velocity analysis of pfClpB1 with ATPγS. 
Ultracentrifugation was performed at 49,000 rpm and 20 °C for the 0.7 mg/ml protein 
samples in 50 mM Tris/HCL pH 7.5, 0.2 M KCl, 20 mM MgCl2, 1 mM EDTA, 2 mM 
β-mercaptoethanol with ATPγS. The apparent sedimentation coefficient distributions 
g(s*) are shown. 
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inhibiting each other because of the lack of specificity. Aggregate reactivation with pfClpB1 or 
KJE chaperone system alone was very successful. Further studies are required to understand the 
mechanism of aggregate reactivation in PfClpB1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Degree of Luciferase reactivation in presence of pfClpB1 
pfClpB1 does not efficiently reactivate luciferase in cooperation with E. coli 
DnaK/DnaJ/GrpE in presence of luciferase. Luciferase was denatured by heat at 45 ℃. 
Then pfClpB1 and co-chaperones were added. The reactivation of luciferase was monitored 
by luminometer. 
No-chaperone: only buffer 1 
KJE: DnaK, DnaJ, GrpE 
Ec_ClpB: E.coli ClpB 
Ec_ClpB+KJE: E.coli ClpB + KJE chaperone system 
pfClpB1: plasmodium falciparum ClpB located to the apicoplast 
pfClpB1+KJE: pfClpB1 + KJE chaperone system 
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Figure 5.6 Degree of Luciferase reactivation in presence of pfClpB1 (Without E.coli ClpB + 
KJE chaperone system for a better scale) 
pfClpB1 does not efficiently reactivate luciferase in cooperation with E. coli DnaK/DnaJ/GrpE 
in presence of luciferase. Luciferase was denatured by heat at 45 ℃. Then pfClpB1 and co-
chaperones were added. The reactivation of luciferase was monitored by luminometer. 
No-chaperone: only buffer 1 
KJE: DnaK, DnaJ, GrpE 
Ec_ClpB: E.coli ClpB 
pfClpB1: plasmodium falciparum ClpB located to the apicoplast 
pfClpB1+KJE: pfClpB1 + KJE chaperone system 
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Further works 
This study suggests that PfClpB1 is able to reactivate disaggregated protein in presence 
of ATP. However, more work is required to figure out the ATP hydrolysis of PfClpB1 and 
protein reactivation in presence of the unknown apicoplast-targeted Plasmodium falciparum co-
chaperones such as the Hsp70 and Hsp40 families. Our data may imply that PfClpB1 chaperone 
activity may help to preserve the activity of the apicoplast targeted protein under environmental 
stress, which may support the survival of Plasmodium.  Lastly, a multiple sequence alignment 
reveals the presence of extra amino acid sequences in the middle domain, whose function is still 
uncharacterized. A better understanding of the 52 amino acid inserts in the middle domain of 
PfClpB1 can help to determine its function. In short, PfClpB1and other apicoplast chaperones 
may become good targets for the development of pharmaceutical drug therapy helping to 
eliminate Apicomplexa-borne diseases. 
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APPENDIX A: SUPPLEMENTARY RESULTS 
 
Table: Preparation phosphate standard 
2.5 mM Phosphate (μl ) DiH2O (μl ) concentration (nmole) 
0 50 0 
1 49 2.5 
2 48 5 
3 47 7.5 
4 46 10 
5 45 12.5 
6 44 15 
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